248 related articles for article (PubMed ID: 8442239)
1. Effects of three immunosuppressive drug protocols on cadaver renal transplantation costs after 4 years of therapy.
Canafax DM; Carleton BC; Matas AJ; Payne WD; Dunn DL; Sutherland DE; Najarian JS
Transplant Proc; 1993 Feb; 25(1 Pt 2):1692-3. PubMed ID: 8442239
[No Abstract] [Full Text] [Related]
2. Prospective randomized comparison of quadruple vs triple therapy for first cadaver transplants with immediate function.
Johnson CP; Slakey DP; Callaluce RD; Browne BJ; Roza AM; Adams MB
Transplant Proc; 1993 Feb; 25(1 Pt 1):585-6. PubMed ID: 8438425
[No Abstract] [Full Text] [Related]
3. An immunosuppressive protocol compatible with the United States kidney transplant diagnosis related grouping.
Stuart FP; Stuart JK; Thistlethwaite JR; Gaber AO; Mayes J
Transplant Proc; 1987 Feb; 19(1 Pt 3):1959-60. PubMed ID: 3152656
[No Abstract] [Full Text] [Related]
4. Intermodal immunosuppression for cadaver renal transplantation: results using antilymphocyte globulin, azathioprine, cyclosporine, and prednisone.
Halloran P; Ludwin D; Bear R; Aprile M; McQuarrie B; Poole R; White N
Transplant Proc; 1987 Feb; 19(1 Pt 3):1931-2. PubMed ID: 3274454
[No Abstract] [Full Text] [Related]
5. Cyclosporine-steroids versus conventional therapy in cadaver kidney transplantation: analysis of a randomized trial at two years.
Gianello P; Squifflet JP; Pirson Y; Stoffel M; Dereme T; Alexandre GP
Transplant Proc; 1987 Feb; 19(1 Pt 3):1867-72. PubMed ID: 3547891
[No Abstract] [Full Text] [Related]
6. A comparison of three immunosuppressive protocols in patients aged over 50 years.
Fryd DS; So SK; Kruse L; Canafax DM; Sutherland DE; Simmons RL; Najarian JS
Transplant Proc; 1987 Feb; 19(1 Pt 2):1530-1. PubMed ID: 3274374
[No Abstract] [Full Text] [Related]
7. Quadruple therapy for cadaver renal transplantation.
Deierhoi MH; Sollinger HW; Kalayoglu M; Belzer FO
Transplant Proc; 1987 Feb; 19(1 Pt 3):1917-9. PubMed ID: 3274452
[No Abstract] [Full Text] [Related]
8. Sri Lankan experience with three immunosuppressive protocols in living related donor kidney transplantation.
Sheriffdeen AH; de Abrew K; Jayasekera G; Nanayakkara S; de Mel CP; Jayasinghe S; Fernando H; Rajakanthan K; Weerasinghe A; Kuruppruarchchi L
Transplant Proc; 1992 Oct; 24(5):1818. PubMed ID: 1412862
[No Abstract] [Full Text] [Related]
9. Cyclosporine levels impact early rejection episodes.
Granger DK; Amin NB; Sorenson AL; Gillingham KJ; Canafax DM; Matas AJ
Transplant Proc; 1994 Oct; 26(5):2513. PubMed ID: 7940771
[No Abstract] [Full Text] [Related]
10. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
[No Abstract] [Full Text] [Related]
11. Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients.
Lewis RL; Canafax DM; Pettit KG; DiCesare J; Kaniecki DJ; Arnold RJ; Roberts MS
Transplant Proc; 1996 Aug; 28(4):2214-7. PubMed ID: 8769203
[No Abstract] [Full Text] [Related]
12. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR
Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180
[No Abstract] [Full Text] [Related]
13. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens.
Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684
[No Abstract] [Full Text] [Related]
14. Ten years of cyclosporine use in renal transplantation: a single-center experience with 479 renal transplants.
Lucan M; Iacob G; Lucan C; Lăpuşan C; Munteanu A; Sîrbu S
Transplant Proc; 2004 Mar; 36(2 Suppl):177S-180S. PubMed ID: 15041332
[TBL] [Abstract][Full Text] [Related]
15. HLA-DR matching is effective in reducing posttransplant costs in renal allograft recipients on triple therapy.
Taylor CJ; Bayne AM; Welsh KI; Morris PJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):210-1. PubMed ID: 8438273
[No Abstract] [Full Text] [Related]
16. Quadruple drug therapy prevents graft loss from acute rejection without increasing mortality.
Light JA; Aquino A; Ali A; Rodriguez R; Ali S
Transplant Proc; 1987 Feb; 19(1 Pt 3):1927-30. PubMed ID: 3547897
[No Abstract] [Full Text] [Related]
17. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
18. Cyclosporine immunosuppression in non-heart-beating cadaver donors.
Asano H; Uchida K; Tominaga Y; Haba T; Sato K; Numano M; Orihara A; Yokoyama I; Takagi H
Transplant Proc; 1992 Oct; 24(5):2042-3. PubMed ID: 1412965
[No Abstract] [Full Text] [Related]
19. Triple-drug regimen for first kidney transplants in developing countries.
Erken U; Erken E; Tansuğ Z; Türkyilmaz R
Transplant Proc; 1992 Oct; 24(5):1843. PubMed ID: 1412875
[No Abstract] [Full Text] [Related]
20. Effect of duration of MALG therapy in a quadruple immunosuppressive protocol.
Stratta RJ; D'Alessandro AM; Armbrust MJ; Pirsch JD; Sollinger HW; Kalayoglu M; Belzer FO
Transplant Proc; 1989 Feb; 21(1 Pt 2):1726-8. PubMed ID: 2652564
[No Abstract] [Full Text] [Related]
[Next] [New Search]
